Johnson & Johnson (JNJ) announced on Tuesday that nipocalimab, its experimental therapy for an autoimmune condition called ...

The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...

Johnson & Johnson said it will initiate a Phase 3 trial of its treatment for systemic lupus erythematosus, or SLE, after a recent study of the therapy met its primary endpoint.

Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic lupus erythematosus (SLE) and the initiation of a ...

Subcutaneous anifrolumab significantly reduces disease activity in patients with moderate to severe systemic lupus erythematosus.

In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

Objectives To examine the association between social determinants of health (SDH) and outcomes in systemic lupus ...

In systemic lupus erythematosus, chronic spontaneous urticaria did not raise SLEDAI scores, but cylindruria, mucosal ulcers, ...

What is Systemic Lupus Erythematosus? Systemic Lupus Erythematosus (SLE) is a chronic disease with many manifestations. It is an autoimmune disease in which the body's immune system is directed ...

Worldwide incidence and prevalence estimates of systemic lupus erythematosus (SLE) vary substantially and are influenced by ethnic and geographic differences, study design and environmental exposures ...